CLEC12A and neoplasm: Consistent with a mounting antitumor response, mice treated with CLL-1 CAR-T cells exhibited significantly decreased tumor cells compared to mock T or PBS-treated mice (Fig. 4e, f), and the hCD45+ CLL1− population in peripheral blood of CAR-T-treated mice was all human T cells (Additional file 7: Figure S6).